AGP Executive Report
Last update: 7 hours agoRare Disease Drug Push: GSK’s momelotinib wins US FDA and EMA orphan drug designation for VEXAS syndrome, with an ATLAS phase II/III trial now advancing a treatment path for a condition with no approved options. Middle East Diplomacy: France hosts a Paris conference bringing Israeli and Palestinian civil society together to keep a two-state solution alive ahead of the G7, ending with a “Call for Action” on ceasefire, settlements and governance. EU Funds & Rule-of-Law: Hungary submits its recovery plan to unlock withheld EU money, moving “super milestones” forward while tightening asset-declaration rules and expanding integrity powers. Defense Spending Debate: Italy signals higher defence outlays but argues allies must rethink priorities for drone- and satellite-driven warfare; in Britain, the defence secretary resigns over underfunding and NATO commitments. Energy & Industry: France prepares a major 10 GW offshore wind tender; Rapidus eyes chip cooperation with UK and Italy; and WuXi AppTec expands drug manufacturing capacity across Europe and beyond. Tech & Society: Robotaxis are set to arrive in Spain by end-2026, raising questions about jobs and safety.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
